AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06442462
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05286008
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Before the induction of anesthesia, normal saline is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
Trial: NCT05885841
Drug: XTR004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At rest: IV bolus injection of XTR004 with a dose range of 2.0-2.5 mCi~At stress: IV infusion of adenosine at a rate of 140 μg/kg/min. IV bolus injection of XTR004 with a dose range of 6.0-7.5 mCi.
Trial: NCT05215418
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive oral capsule
Trial: NCT05393271
Drug: VH4011499
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VH4011499 will be administered.
Trial: NCT05393271
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered.
Trial: NCT06312748
Drug: Placebo for L-Citrulline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Citrulline-matched Placebo tablet
Trial: NCT06312748
Drug: Placebo for BH4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BH4-matched Placebo
Trial: NCT05012397
Drug: RAIN-32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 260 mg once daily orally on Days 1 to 3 and Days 15 to 17 of each 28-day cycle
Trial: NCT05512754
Drug: Ibuprofen 400 mg
RxNorm normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg tablet
Trial: NCT05312879
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets for oral administration.
Trial: NCT05173714
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo tablets (matching the experimental semaglutide) will be administered from the first through ninth months of the drug intervention period.
Trial: NCT05788276
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo tablets
Trial: NCT06255847
Drug: Pomalidomide, cyclophosphamide combined with dexametha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The starting dose of pomalidomide was 2 mg in all cases，the starting dose of cyclophosphamide was 50 mg/day.If the adverse event is attributable to a specific study drug, the dose is reduced accordingly for that drug; if the adverse event is associated with multiple drugs, the dose is reduced appropriately for one of the predominantly associated drugs at the discretion of the investigator; and if multiple adverse events occur concurrently, the dose should be adjusted according to the guidelines for the most severe toxicity.
Trial: NCT06313983
Drug: Lapatinib+Capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take the pills according to the instructions
Trial: NCT05233722
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of 800 mg of calcium tablets
Trial: NCT04844450
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered subcutaneously.
Trial: NCT06462612
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching capsules administered orally, once daily
Trial: NCT04959825
Drug: Melatonin 5 mg
RxNorm normalized name: melatonin 5 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: study the effect of preoperative oral melatonin 5mg on isoflurane consumption and postoperative pain
Trial: NCT06314490
Drug: nL-SCN2A-002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized antisense oligonucleotide
Trial: NCT05973773
Drug: TAS6417
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablets
Trial: NCT01021163
Drug: N-acetylcysteine, saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inject 100 mg/kg of N-acetylcysteine or the equivalent amount of saline for 15 minutes before the skin incision, then continuously inject 40 mg/kg/day of N-acetylcysteine or the equivalent amount of saline during the next 24 hours.
Trial: NCT03944902
Drug: Cohort 2: Dose Escalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If no dose limiting toxicities, 3 additional participants will be enrolled in this cohort. Participants will receive a fixed dose of Niraparib and CB-839, 800mg.
Trial: NCT05649722
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo inhalation using a capsule-based dry powder inhaler device.
Trial: NCT06226883
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo (identical appearance to MORF-057) administered orally.
Trial: NCT03652870
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose and magnesium stearate tablet to be used as a placebo.
Trial: NCT06706076
Drug: BH-30643
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BH-30643 will be provided as either 10 mg or 40 mg capsules. Subjects will take BH-30643 orally depending on their dose level assignment.
Trial: NCT06556563
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline solution) dose throughout this study is 200 mg IV Q3W for a maximum of 35 cycles.
Trial: NCT05675410
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05675410
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05675410
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05564390
Drug: Decitabine and Cedazuridine
RxNorm normalized name: cedazuridine / decitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06088654
Drug: IPH6501
FDA approved: no
EMA approved: no
PMDA approved: no
Description: phase 1 (dose finding) and phase 2 (dose expansion)
Trial: NCT06445959
Drug: Decitabine/cedazuridine
RxNorm normalized name: decitabine/cedazuridine 35 mg-100 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by PO
Trial: NCT05714085
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for vericiguat administered orally once daily in tablet form
Trial: NCT06132893
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo taken once daily
Trial: NCT06588686
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04791332
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered orally.
Trial: NCT05197049
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered by SC injection.
Trial: NCT06496178
Drug: Investigator's Choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetuximab
Trial: NCT06058377
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT06058377
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05222009
Drug: PEG-rhG-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-rhG-CSF, 3mg, D1, Q3W, subcutaneous injection, until stop using PD-(L)1 inhibitor, progressive disease (PD) or unacceptable toxicity. Meanwhile, the original maintenance regimen--PD-(L)1 inhibitor ± VEGFR/EGFR TKI/Ab--continues.
Trial: NCT05222009
Drug: PEG-rhG-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-rhG-CSF, 6mg, D1, Q3W, subcutaneous injection, until stop using PD-(L)1 inhibitor, progressive disease (PD) or unacceptable toxicity. Meanwhile, the original maintenance regimen--PD-(L)1 inhibitor ± VEGFR/EGFR TKI/Ab--continues.
Trial: NCT04947826
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05493228
Drug: Precedex Injectable Product
RxNorm normalized name: Precedex Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Precedex activates 2-adrenoceptors, and causes the decrease of sympathetic tone, with attenuation of the neuroendocrine and hemodynamic responses to anesthesia and surgery; it reduces anesthetic and opioid requirements; and causes sedation and analgesia. it is used before and/or during surgical
Trial: NCT05124002
Drug: Recombinant Human Adenovirus Type 5
RxNorm normalized name: adenovirus, type 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H101 will be intratumorally injected 3 days before HAIC. Dosage of H101: 1 vial (5.0 × 10\^11 vp) if the maximum diameters of lesion ≤ 5 cm, 2 vials (1.0 × 10\^12 vp) if the maximum diameters of lesion ≤ 10 cm, 3 vials (1.5 × 10\^12 vp) if the maximum diameters of lesion is \> 10 cm.
Trial: NCT06559306
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo tablets will be administered orally.
Trial: NCT06559306
Drug: Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRI/SNRI will be administered orally.
Trial: NCT06700720
Drug: Dose 1 YN001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose 1 YN001 will be administered on Day 1 and Day 5 of each week from Week 1 to Week 12, and on Day 1 of Week 13, 25 times in total.
Trial: NCT06700720
Drug: Dose 2 YN001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose 2 YN001 will be administered on Day 1 of each week from Week 1 to Week 13, 13 times in total.
Trial: NCT04844411
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered orally.
Trial: NCT04782505
Drug: DWJ1248
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camostat mesylate Tablet from Daewoong
Trial: NCT06449651
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administrated intravenously.
Trial: NCT04655807
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered as SC injection.
Trial: NCT06095102
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered orally.
Trial: NCT05541315
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered orally.
Trial: NCT04937543
Drug: inhaled beclametasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adding belcamethasone to standard of care for Covid 19 positive patients
Trial: NCT05731050
Drug: NM8074
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NM8074 will be administered as an intravenous infusion. All enrolled subjects will receive a dose of 15 mg/kg NM8074 once every two weeks for a total of 6 doses from Day1 to Day 84.~For Soliris-treated PNH subjects, admission and dosing of NM8074 on Day 1 should be scheduled to coincide with the next scheduled dose of Soliris (i.e., 14 ± 2 days after the last Soliris dose). Soliris should NOT be administered on Day 1 or at any time thereafter during course of the study.~Subjects in the treatment groups will receive a dose of 15 mg/kg of NM8074 on Day 1, which will be administered during the study visit by the site staff. During the remainder of the treatment period, subjects will be given another 15 mg/kg dose every two weeks at approximately the same time. On days of scheduled study visits at the Investigation Site, the dose must be administered after blood work is completed.
Trial: NCT06477991
Drug: Tireilizumab（PD-1 inhibitor）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant immunotherapy phase :~1. Pharmaceuticals: Tireilizumab: 200mg, intravenous infusion, Q3W, at least 4 cycles, the number of specific neoadjuvant immunotherapy cycles was determined according to the results of MRD dynamic monitoring.~2. MRD dynamic monitoring time node: dynamic monitoring at the initial diagnosis and after the fourth cycle of neoadjuvant immunotherapy. Blood monitoring points were 1-2 weeks after immunotherapy. If the two consecutive MRDs were negative, the watch and wait strategy was adopted. If the MRD was still positive after 8 cycles of neoadjuvant immunotherapy, surgical treatment was performed.
Trial: NCT06642363
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo group will take one capsule containing corn starch in a wrapped and covered form and the appearance of ASX supplementation (blinding).
Trial: NCT04904237
Drug: Aza-Ven-allo-HSCT
RxNorm normalized name: Apis mellifera ven protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aaa-ven treatment followed by allo-HCTS with reduced toxicity conditioning (RTC) of Fludarabine, Busulifan and Melphalan
Trial: NCT06050577
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weeks 1-4: 3 mg of oral placebo once daily. Weeks 5-52: 7 mg of placebo once daily as maintenance dose. Dose may be increased to 14 mg of placebo once daily as maintenance dose after 2 months if glucose levels are out of range.
Trial: NCT05306444
Drug: CLN-418
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) administration
Trial: NCT05498428
Drug: Direct Oral Anticoagulant (DOAC)
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DOAC will be administered orally.
Trial: NCT05498428
Drug: Low Molecular Weight Heparin (LMWH)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LMWH will be administered subcutaneously.
Trial: NCT05665608
Drug: Optimal Medical Therapy (OMT)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated according to Optimal Medical Therapy defined by the following guidelines:~1. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes~2. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
Trial: NCT04628026
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered in Induction cycle 1, Induction cycle 2 and in the chemo consolidation therapy in addition to the standard chemotherapy
Trial: NCT06343298
Drug: MANP
RxNorm normalized name: Multimineral/Multivitamin Oral Tablet [MANPOWER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MANP (modified atrial natriuretic peptide) is a peptide that is being developed for treatment of difficult to control/resistant hypertension.
Trial: NCT04745026
Drug: GWP42003-P
RxNorm normalized name: P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GWP42003-P oral solution (100 milligrams per milliliter \[mg/mL\] cannabidiol \[CBD\] in sesame oil with anhydrous ethanol, ethanol \[10% v/v\] sweetener \[sucralose\], and strawberry flavoring), administered twice a day (morning and evening)
Trial: NCT04745026
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo to match GWP42003-P oral solution containing sesame oil with anhydrous ethanol, sweetener (sucralose), strawberry flavoring, and beta carotene, administered twice a day (morning and evening)
Trial: NCT06544616
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered intramuscularly.
Trial: NCT05552157
Drug: Matching Placebo (Remternetug)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as subcutaneous injection of placebo every 12 weeks
Trial: NCT05937581
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% w/v NaCI, IV Administration
Trial: NCT05090891
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered QD orally.
Trial: NCT05268497
Drug: Antidepressant
RxNorm normalized name: Antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant will be administered orally.
Trial: NCT05996471
Drug: Standard of care (SOC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-baseline SOC antiretroviral therapy (ART) will be administered.
Trial: NCT06049017
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet will be administered orally.
Trial: NCT05269316
Drug: IMP9064
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMP9064 Monotherapy administered for 21 days
Trial: NCT05702034
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered orally
Trial: NCT05327816
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as intramuscular injection.
Trial: NCT05762471
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive GSBR-1290 or matching Placebo
Trial: NCT05930002
Drug: Standared managment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (Vitamin C 500mg tablet twice daily, Vitamin D3 2000-4000 IU/day, Zinc 75mg tablet once daily for two weeks
Trial: NCT05042362
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo orally once daily
Trial: NCT05970783
Drug: Jincaopian Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jincaopian Tablets 0.2g tid p.o.
Trial: NCT05085808
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered to ICU patients who need pharmacological intervention for delirium, if they are randomized to the placebo arm.
Trial: NCT06619210
Drug: HL231 Dose 1/2/3/4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HL231 Solution for Inhalation, dose 1/2/3 (Part A) , dose 2/4（Part B） single dose, oral inhalation by PARI BOY nebulizer
Trial: NCT06276374
Drug: Patients who are scheduled to undergo carotid artery stenting
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Arm A : Single antiplatelet therapy (SAPT) with aspirin or clopidogrel~  - 1 month of dual antiplatelet therapy(100mg aspirin q.d. and 75mg clopidogrel q.d.)→ Randomization → 11 months of single antiplatelet therapy (100mg aspirin q.d. or 75mg clopidogrel q.d.)~* Arm B : Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel - 1 month of dual antiplatelet therapy(100mg aspirin q.d. and 75mg clopidogrel q.d.) → Randomization → 11 months of dual antiplatelet therapy (100mg aspirin q.d. and 75mg clopidogrel q.d.)
Trial: NCT05879926
Drug: Ovarian Function Suppression + Aromatase Inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitor co-administered with a GnRH agonist for 5 years. The choice of AI is per investigator discretion. The choice of GnRH agonist and dosing schedule is per investigator's discretion. Options commonly include goserelin, leuprolide, or triptorelin given monthly or every-three-months. The dose and schedule of AI should be consistent with the drug package insert. Endocrine treatment beyond 5 years is at the investigator's discretion. Bilateral oophorectomy may substitute for ovarian suppression if desired.
Trial: NCT04633213
Drug: HBM9036 0.25% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic Solution
Trial: NCT04633213
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic Solution
Trial: NCT06127940
Drug: Temporary Stopping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temporary stop of sotorasib during SBRT
Trial: NCT06469944
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered via oral tablet.
Trial: NCT06469944
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered via IV infusion.
Trial: NCT05458479
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All participants in the study will receive open-label treatment with orally administered fluoxetine for the full duration of the 16-week trial. Fluoxetine is a selective serotonin reuptake inhibitor. It is approved for the management of major depressive disorder in adults.
Trial: NCT05897385
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal 20ml of 0.9% normal saline
Trial: NCT05621759
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nitrogen mustard alkylating agent produced by Bristol-Myers Squibb.
Trial: NCT04847063
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Part of Arm 3: intraperitoneal (IP) Doxorubicin co-therapy 15 mg/m2 for 60 minutes, given at time = 0 with cisplatin
Trial: NCT06412666
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT05537233
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection placebo up to 1 mg per week in addition to standard closed-loop therapy
Trial: NCT04938765
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml of normal saline bolus will be administered to the control group over 10 mins.
Trial: NCT06384456
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mL of 100mg/mL normal saline will be administered into the surgical wound prior closure.